Search Results | American Association of Immunologists

1-20 of 46

2 3

Sort by

Sort Order Select

Journal Articles

Pre-transplant treatment with a GM-CSF-secreting myeloid leukemia cell vaccine combined with autologous BMT significantly improves the graft-versus-leukemia response (131.43)

Jenny Zilberberg, Thea Friedman, Robert Korngold

J Immunol (2010) 184 (1_Supplement): 131.43.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.43

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

Lentiviral-siRNA blockade of immunosuppressive genes increases DC vaccine efficacy. (131.42)

Lori Lebson, Jason Rosenzweig, Justin Manicini, Katharine Whartenby

J Immunol (2010) 184 (1_Supplement): 131.42.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.42

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

Administration of a vaccine composed of dendritic cells pulsed with premalignant oral lesion lysate results in an increase in CD4+ and CD8+ T cells and a decrease in Foxp3+ cells in tongues of mice bearing carcinogen-induced premalignant oral lesions. (131.24)

Anna-Maria Clark, M. Rita Young

J Immunol (2010) 184 (1_Supplement): 131.24.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.24

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

Targeting CD73 to improves tumor immunotherapy (131.23)

Bin Zhang, Dachuan Jin, Jie Fan, Long Wang, Linda Thompson, Aijie Liu, Ben Daniel, Tahiro Shin, Tyler Curiel

J Immunol (2010) 184 (1_Supplement): 131.23.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.23

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

In vivo administration of artificial Antigen Presenting Cells licenses low avidity T cells for treatment of cancer (131.13)

Mathias Oelke, Stefano Ugel, Alessia Zoso, Carmela De Santo, Yu Li, Ilaria Marigo, Paola Zanovello, Elisa Scarselli, Barbara Cipriani, Vincenzo Bronte, Jonathan P. Schneck

J Immunol (2010) 184 (1_Supplement): 131.13.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.13

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

MUC1-specific Th1 immunotherapy induce differential levels and proportions of "inducible" and "natural" CD4 TReg cell subpopulations that results in enhanced tumor immunity and increased ovarian cancer patient survival (131.38)

Mark Dobrzanski, Kathleen Rewers-Felkins, Khaliquzzaman Samad, William Robinson, Stephen Wright

J Immunol (2010) 184 (1_Supplement): 131.38.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.38

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

Activation of omental immune aggregates: a potential tumor therapy (131.37)

Abigail Sedlacek, Scott Gerber, Edith Lord

J Immunol (2010) 184 (1_Supplement): 131.37.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.37

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

Nanoparticle [Gd@C82(OH)22]n induces dendritic cell maturation and promotes Th1 immune responses (131.2)

De Yang, Yuliang Zhao, Hua Guo, Yana Li, Poonam Tewary, Ning Zhang, Joost Oppenheim

J Immunol (2010) 184 (1_Supplement): 131.2.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.2

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

Vaccination with tumor cell lysate plus CpG oligodeoxynucleotides elicits tumor-specific T cells with potent antitumor efficacy in adoptive immunotherapy (131.31)

Maki Shindo, Wei Chen

J Immunol (2010) 184 (1_Supplement): 131.31.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.31

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

Adoptive co-transfer of tumor specific CD4⁺ T cells awakens host protective immunity to MHC-II^- ovarian cancer through CD40-mediated licensing of dendritic cells and CCL5 secretion. (131.14)

Yolanda Nesbeth, Diana Martinez, Seiko Toraya, Uciane Scarlett, Juan Cubillos-Ruiz, Melanie Rutkowski, Jose Conejo-Garcia

J Immunol (2010) 184 (1_Supplement): 131.14.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.14

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

CpG-conjugated apoptotic tumor cells elicit potent tumor immunity (131.41)

Hidekazu Shirota, Dennis Klinman

J Immunol (2010) 184 (1_Supplement): 131.41.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.41

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

Evaluation of cellular therapies utilizing a fluorine-based magnetic resonance imaging (MRI) tracer agent (131.40)

Brooke Helfer, Anthony Balducci, Robbie Mailliard, Amy Wesa, Eric Ahrens

J Immunol (2010) 184 (1_Supplement): 131.40.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.40

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

Development of an inducible MyD88.CD40 gene switch for potent anti-tumor dendritic cell (DC) vaccines (131.22)

Priyadharshini Narayanan, Natalia Lapteva, Mamatha Seethammagari, Kevin Slawin, David Spencer

J Immunol (2010) 184 (1_Supplement): 131.22.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.22

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

SA-4-1BBL serves as an effective immunostimulatory component of HPV-16 E7 protein based therapeutic vaccine in a mouse model of cervical cancer (131.21)

Rajesh Sharma, Abhishek Srivastava, Esma Yolcu, Rich-Henry Schabowsky, Haval Shirwan

J Immunol (2010) 184 (1_Supplement): 131.21.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.21

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

Abrogation of SHP-1 in tumor-specific effector T cells during adoptive immunotherapy of disseminated leukemia (131.15)

Ingunn Stromnes, Carla Fowler, Joseph Blattman, Xiaoxia Tan, Philip Greenberg

J Immunol (2010) 184 (1_Supplement): 131.15.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.15

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

Selective targeting of tumor vasculature by cytotoxic T lymphocytes specific for tumor endothelial marker-8 (131.36)

Supriya Perambakam, Esther Ro, David Peace

J Immunol (2010) 184 (1_Supplement): 131.36.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.36

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

Interleukin-2 significantly upregulates CD86 expression on T cells during cytokine therapy (131.35)

Ananta Paine, Hartmut Kirchner, Mathias Oelke, Rainer Blasczyk, Britta Eiz-Vesper

J Immunol (2010) 184 (1_Supplement): 131.35.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.35

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

Enhanced IL-2 signaling renders IL-12 primed CD8+ T-cells superior in adoptive immunotherapy. (131.20)

Dominique Lisiero, Horacio Soto, Linda Liau, Robert Prins

J Immunol (2010) 184 (1_Supplement): 131.20.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.20

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

Development of tumor-associated antigen (TAA)-specific T cell responses in heavily-tolerized mice requires vaccination with peptide variants that target T cells with decreased responsiveness to TAA (131.7)

Charles Kemmler, Jill Slansky

J Immunol (2010) 184 (1_Supplement): 131.7.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.7

Published: 01 April 2010

View article

Add to Citation Manager

Journal Articles

Anti-melanoma immunity promoted by cutaneous genetic immunizations requires agonistic signaling via the nerokinin-1 receptor (131.6)

Alicia Mathers, Olga Tkacheva, Brian Janelsins, William Schufeski, Adrian Morelli, Adriana Larregina

J Immunol (2010) 184 (1_Supplement): 131.6.

DOI: https://doi.org/10.4049/jimmunol.184.Supp.131.6

Published: 01 April 2010

View article

Add to Citation Manager

2 3

NARROW

Pre-transplant treatment with a GM-CSF-secreting myeloid leukemia cell vaccine combined with autologous BMT significantly improves the graft-versus-leukemia response (131.43)

Lentiviral-siRNA blockade of immunosuppressive genes increases DC vaccine efficacy. (131.42)

Administration of a vaccine composed of dendritic cells pulsed with premalignant oral lesion lysate results in an increase in CD4+ and CD8+ T cells and a decrease in Foxp3+ cells in tongues of mice bearing carcinogen-induced premalignant oral lesions. (131.24)

Targeting CD73 to improves tumor immunotherapy (131.23)

In vivo administration of artificial Antigen Presenting Cells licenses low avidity T cells for treatment of cancer (131.13)

MUC1-specific Th1 immunotherapy induce differential levels and proportions of "inducible" and "natural" CD4 TReg cell subpopulations that results in enhanced tumor immunity and increased ovarian cancer patient survival (131.38)

Activation of omental immune aggregates: a potential tumor therapy (131.37)

Nanoparticle [Gd@C82(OH)22]n induces dendritic cell maturation and promotes Th1 immune responses (131.2)

Vaccination with tumor cell lysate plus CpG oligodeoxynucleotides elicits tumor-specific T cells with potent antitumor efficacy in adoptive immunotherapy (131.31)

Adoptive co-transfer of tumor specific CD4⁺ T cells awakens host protective immunity to MHC-II^- ovarian cancer through CD40-mediated licensing of dendritic cells and CCL5 secretion. (131.14)

CpG-conjugated apoptotic tumor cells elicit potent tumor immunity (131.41)

Evaluation of cellular therapies utilizing a fluorine-based magnetic resonance imaging (MRI) tracer agent (131.40)

Development of an inducible MyD88.CD40 gene switch for potent anti-tumor dendritic cell (DC) vaccines (131.22)

SA-4-1BBL serves as an effective immunostimulatory component of HPV-16 E7 protein based therapeutic vaccine in a mouse model of cervical cancer (131.21)

Abrogation of SHP-1 in tumor-specific effector T cells during adoptive immunotherapy of disseminated leukemia (131.15)

Selective targeting of tumor vasculature by cytotoxic T lymphocytes specific for tumor endothelial marker-8 (131.36)

Interleukin-2 significantly upregulates CD86 expression on T cells during cytokine therapy (131.35)

Enhanced IL-2 signaling renders IL-12 primed CD8+ T-cells superior in adoptive immunotherapy. (131.20)

Development of tumor-associated antigen (TAA)-specific T cell responses in heavily-tolerized mice requires vaccination with peptide variants that target T cells with decreased responsiveness to TAA (131.7)

Anti-melanoma immunity promoted by cutaneous genetic immunizations requires agonistic signaling via the nerokinin-1 receptor (131.6)

Publications

Submit a Manuscript

General Information

Journal Services

Publications

Submit a Manuscript

General Information

Journal Services

This Feature Is Available To Subscribers Only